Amsbio has announced the launch of a cell migration assays designed for fully automated high throughput screening (HTS) utilising high-content screening (HCS) and high-content imaging (HCI) systems.
The Oris Pro 384 cell migration assay uses a non-toxic biocompatible gel (BCG) to form a centrally located and temporary cell-free zone on cell culture surfaces in a 384-well format.
After cell seeding the BCG dissolves to reveal a detection zone into which the migration of cells can be observed either in real time or after further experimental processing.
This breakthrough product enables researchers to capture and quantify cell migration data while improving assay efficiency and reducing assay costs.
Measurement of cell migration enables researchers to better understand the impact of candidate therapeutic compounds on biological pathways and cellular behaviour.
This 384-well format assay adds to the 96-well range of Oris Pro assays available from Amsbio and will play an important role in accelerating the development of new therapeutics for wound healing, cancer treatment and other diseases impacted by the movement of cells.
